GENOMIC HEALTH, INC.
Redwood City, CA US
|GENOMIC HEALTH, INC. Patent applications|
|Patent application number||Title||Published|
|20140206545||GENE EXPRESSION MARKERS FOR PREDICTION OF PATIENT RESPONSE TO CHEMOTHERAPY - The present invention relates to gene sets useful in assessing prognosis and/or predicting the response of cancer, e.g. colorectal cancer to chemotherapy. In addition, the invention relates to a clinically validated cancer test, e.g. colorectal test, for assessment of prognosis and/or prediction of patient response to chemotherapy, using expression analysis. The present invention accommodates the use of archived paraffin embedded biopsy material for assay of all markers in the relevant gene sets and therefore is compatible with the most widely available type of biopsy material.||07-24-2014|
|20130274127||GENE EXPRESSION MARKERS FOR PREDICTION OF RESPONSE TO PHOSPHOINOSITIDE 3-KINASE INHIBITORS - The present invention provides methods for predicting a likelihood that a tumor cell will be sensitive or resistant to a phosphoinositide 3-kinase (PI3K) inhibitor. The methods generally involve determining an expression level of a gene product that correlates with sensitivity or resistance to a PI3K inhibitor. The present invention also provides methods for increasing sensitivity of a tumor cell to a PI3K inhibitor by contacting the tumor cell with an activator or inhibitor of a gene product that correlates with sensitivity or resistance to a PI3K inhibitor.||10-17-2013|
|20130196321||Gene Expression Profile Algorithm and Test for Determining Prognosis of Prostate Cancer - The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes, or their co-expressed genes, from a biological sample obtained from a prostate cancer patient. The genes may be grouped into functional gene subsets for calculating a quantitative score useful to predict a likelihood of a clinical outcome for a prostate cancer patient.||08-01-2013|
|20130102492||GENE EXPRESSION MARKERS FOR COLORECTAL CANCER PROGNOSIS - A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.||04-25-2013|
|20120270228||PREDICTORS OF PATIENT RESPONSE TO TREATMENT WITH EGF RECEPTOR INHIBITORS - The present invention provides methods and compositions to facilitate determining whether an EGFR-expressing cancer in an individual is an EGFR inhibitor-responsive cancer, as well as methods for determining the likelihood that a patient having an EGFR-expressing cancer will exhibit a beneficial response to an EGFR inhibitor therapy. The methods generally involve determining a normalized expression level of a gene product that correlates with EGFR inhibitor responsiveness.||10-25-2012|
|20090258795||Gene expression markers for prediction of patient response to chemotherapy - A method of predicting clinical outcome in a subject diagnosed with cancer and treated with chemotherapy comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample comprising cancer cells obtained from the subject.||10-15-2009|
Patent applications by GENOMIC HEALTH, INC.